SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-017890
Filing Date
2023-05-04
Accepted
2023-05-04 16:18:41
Documents
65
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20230331.htm   iXBRL 10-Q 2654446
2 EX-4.3 algs-ex4_3.htm EX-4 33073
3 EX-31.1 algs-ex31_1.htm EX-31 21688
4 EX-31.2 algs-ex31_2.htm EX-31 21686
5 EX-32.1 algs-ex32_1.htm EX-32 12389
6 EX-32.2 algs-ex32_2.htm EX-32 12384
  Complete submission text file 0000950170-23-017890.txt   7998135

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT algs-20230331.xsd EX-101.SCH 58525
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT algs-20230331_lab.xml EX-101.LAB 462537
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT algs-20230331_pre.xml EX-101.PRE 323216
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT algs-20230331_def.xml EX-101.DEF 179455
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT algs-20230331_cal.xml EX-101.CAL 43081
59 EXTRACTED XBRL INSTANCE DOCUMENT algs-20230331_htm.xml XML 1227086
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 23889036
SIC: 2836 Biological Products, (No Diagnostic Substances)